Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03532009 · ClinicalTrials.gov registry record · Phase 2
Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 182
- Enrollment target
NCT03532009 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 182 participants.
The verdict
NCT03532009, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 182 participants
- Enrollment target
Study Summary
This is an international, multicentre, parallel-group, randomised, double-blind, placebo controlled, phase II study to evaluate the benefits and risks of using sodium zirconium cyclosilicate (ZS) to initiate and intensify renin angiotensin aldosterone system inhibitor (RAASi) therapy in heart failure patients.
Interventions
- DRUG Placebo
- DRUG Sodium Zirconium Cyclosilicate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2018-06-26 |
| Est. Completion | 2020-05-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03532009
The ClinicalTrials.gov registry entry for NCT03532009 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03532009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03532009 about?
NCT03532009 is a clinical study titled "Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure". This is an international, multicentre, parallel-group, randomised, double-blind, placebo controlled, phase II study to evaluate the benefits and risks of using sodium zirconium cyclosilicate (ZS) to initiate and intensify renin angiotensin aldosterone system inhibitor (RAASi) therapy in heart failur...
What is the current status of trial NCT03532009?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2018-06-26. Estimated completion is 2020-05-22.
What interventions are being tested in trial NCT03532009?
The interventions under investigation include: Placebo (DRUG), Sodium Zirconium Cyclosilicate (DRUG).
Who is sponsoring clinical trial NCT03532009?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.